About TRV045
Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders.
S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. Trevena's discovery efforts have provided innovative insight into the function of the S1P receptor, resulting in a family of compounds that are capable of engaging this receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of chemotherapy-induced peripheral neuropathy, TRV045 demonstrated activity with reduced associated lymphopenia.
Per latest 10Q "We expect to file an IND application with the FDA for TRV045 in the first half of 2021."- Trevena funded
Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders.
S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. Trevena's discovery efforts have provided innovative insight into the function of the S1P receptor, resulting in a family of compounds that are capable of engaging this receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of chemotherapy-induced peripheral neuropathy, TRV045 demonstrated activity with reduced associated lymphopenia.
Per latest 10Q "We expect to file an IND application with the FDA for TRV045 in the first half of 2021."- Trevena funded